Andrew Castellanos, MD
Internal Medicine · Cincinnati, OHNPI 1144409392
Payments from drug & device makers
Across 46 payments — averaging $65.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$1K
- Neurocrine Biosciences, Inc.$507
- Avanir Pharmaceuticals, Inc.$369
- Otsuka America Pharmaceutical, Inc.$298
- Teva Pharmaceuticals USA, Inc.$257
- Abiomed$163
- plus $323 from 7 others
What the payments were for
- Food & beverage$2,95098%
- Education$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 20 | $1,083 |
| Neurocrine Biosciences, Inc. | 5 | $507 |
| Avanir Pharmaceuticals, Inc. | 3 | $369 |
| Otsuka America Pharmaceutical, Inc. | 5 | $298 |
| Teva Pharmaceuticals USA, Inc. | 3 | $257 |
| Abiomed | 2 | $163 |
| Urovant Sciences Inc | 1 | $125 |
| Johnson & Johnson | 1 | $91 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Alpha Cognition USA, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| AbbVie | 1 | $13 |
| Sun Pharmaceutical Industries Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,000 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 2,385 | $806,187 |
| IngrezzaValbenazine Tosylate | 145 | $556,256 |
| TrulicityDulaglutide | 437 | $270,010 |
| Invega SustennaPaliperidone Palmitate | 86 | $254,245 |
| NuplazidPimavanserin Tartrate | 73 | $240,313 |
| XifaxanRifaximin | 151 | $227,754 |
| GemtesaVibegron | 750 | $194,804 |
| JardianceEmpagliflozin | 465 | $150,673 |
| XareltoRivaroxaban | 409 | $134,678 |
| NuedextaDextromethorphan Hbr/Quinidine | 150 | $113,217 |
| JanuviaSitagliptin Phosphate | 301 | $87,418 |
| EntrestoSacubitril/Valsartan | 237 | $71,631 |
| Atorvastatin Calcium | 4,753 | $63,335 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 388 | $61,291 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $55,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $507 | $556,256145 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto, Risperdal Consta | $91 | $415,171515 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,083 | $240,31373 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $23 | $194,804750 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $369 | $113,217150 claims |
| AbbVieLinzess | $13 | $44,43976 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $298 | $41,76414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cincinnati
- Antoinette PragalosCincinnati$27.8M
- Charles EgerCincinnati$8.7M
- Douglas LoganCincinnati$4.7M
- Leela VrishabhendraCincinnati$3.4M
- Traci TurnerCincinnati$645K
- Vincent MartinCincinnati$398K
- Lisa LarkinCincinnati$276K
- Mark EckmanCincinnati$255K
- Kay JohnsonCincinnati$184K
- Steven FolkerthBeavercreek$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.